Temozolomide and olaparib for the treatment of an ARID1A-mutated uterine carcinosarcoma: A case report
Chrissy Liu, Yasmin Abozenah, Thomas J. Rutherford, Vaagn Andikyan, Adrian Kohut, Matthew L. Anderson · 2026
Read Temozolomide and olaparib for the treatment of an ARID1A-mutated uterine carcinosarcoma: A case report by Chrissy Liu, Yasmin Abozenah, Thomas J. Rutherford, Vaagn Andikyan, Adrian Kohut, Matthew L. Anderson (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13589090.txt.
Description
Chrissy Liu and co-authors present a 2026 case report on a gene-guided drug pair for a rare womb cancer. Uterine carcinosarcoma is harsh, and a common gene flaw in it, ARID1A, may open a weak point. Two drugs that strain DNA repair could hit that weak point as a pair. A woman of 54 with stage IIIB disease carried the flaw. Her cancer spread to one lung spot soon after first-line care.
She took the pair in three-week cycles off label. After four cycles, scans showed a full response. She stays in remission, with clean blood marks and no tumor DNA found. Blood platelet counts fell hard at times but recovered. One case can not prove a therapy, yet it earns the pair a formal trial.
Catalog record
| CREATOR | Chrissy Liu, Yasmin Abozenah, Thomas J. Rutherford, Vaagn Andikyan, Adrian Kohut, Matthew L. Anderson |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |